Egfr Exon 19 Deletions - Pharma

Relevant Publications

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study.

Issue Release: 2024

A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma.

Issue Release: 2024

Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report.

Issue Release: 2024

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an Enabled Drug Discovery Platform.

Issue Release: 2024

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.

Issue Release: 2024

Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors.

Issue Release: 2024

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.

Issue Release: 2024

EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.

Issue Release: 2024

Case report: fusion mutation combined with amplification responds to EGFR-TKI therapy.

Issue Release: 2024

Current management of uncommon EGFR mutations in non-small cell lung cancer.

Issue Release: 2024

Activity of afatinib in patients with NSCLC harboring novel uncommon mutations with or without co-mutations: a case report.

Issue Release: 2024

Molecular analysis of genetic mutations in non-small cell lung cancer in Morocco.

Issue Release: 2024

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis.

Issue Release: 2024

Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.

Issue Release: 2024

Molecular Testing for Mutation in Moroccan NSCLC Patients: CHU Hassan II-Fez Experience.

Issue Release: 2024

The Epidermal Growth Factor, Anaplastic Lymphoma Kinase, and ROS Proto-oncogene 1 Mutation Profile of Non-Small Cell Lung Carcinomas in the Turkish Population: A Single-Center Analysis.

Issue Release: 2024

Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images.

Issue Release: 2024

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC.

Issue Release: 2024

A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib.

Issue Release: 2024

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.

Issue Release: 2023

What is Generic Competition?

What Role Does Cellular Stress Play in Disease?

What Should Be Included in Patient Education Materials?

What Are the Challenges of Clinical Trials?

What Roles Do Pharmacists Play in Pharma?

What are the Key Cellular Stress Pathways?

What is a New Drug Application (NDA)?

What is Pharmaceutical Science?

What Causes Adverse Drug Events?

What is Pharma?

Partnered Content Networks

Relevant Topics